Clinical Trial Update: In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop [Phase 3]

View source ↗

Summary

Phase 3 trial updating that LAENNEC (human placenta hydrolysate) is being evaluated for efficacy and safety when given as an intravenous infusion in patients wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcoholic Liver Disease
• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• LAENNEC (Human placenta hydrolysate)

Snippet

Sponsor: Green Cross Wellbeing | Conditions: Chronic Liver Disease | Phase 3 | Status: RECRUITING